A peer-reviewed journal that offers evidence-based clinical information and continuing education for dentists.

FDA Shelves Emergency Authorization for Blood Plasma COVID-19 Treatment


Citing the absence of strong data showing effectiveness, the United States Food and Drug Administration (FDA) decided to wait on issuing an emergency authorization for a blood plasma treatment for COVID-19. The treatment involves transferring blood plasma from people who have recovered from COVID-19 to those fighting the infection with the hopes that the antibodies will transfer from the well to the sick. However, results from clinical trials—including one conducted by the Mayo Clinic with more than 66,000 patients—have not strongly demonstrated efficacy. FDA officials will continue to review available data on the blood plasma treatment. Read more here.

Leave A Reply

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy